Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy

• Main Authors: Hirotoshi Yasui, Kazuhide Sato, Yoshihiro Takeyama, Toshio Kato, Hiroyuki Hashimoto, Yasutaka Fukui, Nagashima Yoshihisa, Matsuyoshi Maeda, Hideo Gonda, Ryujiro Suzuki
• Format: Article
• Language: English
• Published: Karger Publishers 2014-08-01
• Series: Case Reports in Oncology
• Subjects: Carcinoma of unknown primary site; Bronchoscopy; Immunohistochemistry; Carboplatin + paclitaxel + bevacizumab + erlotinib; Maintenance chemotherapy
• Online Access: http://www.karger.com/Article/FullText/366268

About 3% of all cancer patients suffer from carcinoma of unknown primary site (CUP). In spite of its rarity, we will encounter them. While CUPs manifest a wide variety of clinical presentations, they have often resulted in poor prognosis. Although platinum/taxane combination chemotherapy, e.g. carboplatin (CBDCA) + paclitaxel (PTX) is widely used for patients suffering from CUP, the response rate is only about 30-40% and the median overall survival (OS) is only 9 months, which means that improvement is needed. Among the new regimens, the combination of CBDCA, PTX, bevacizumab (BEV) and erlotinib is thought to be highly promising. Herein, we report a case with CUP treated with this regimen and his maintenance therapy. Our patient was a 75-year-old man who was admitted with a left neck lump. CT revealed systemic massive lymphadenopathy. In spite of various investigations for primary origin, he was diagnosed with CUP and treated with CBDCA + PTX + BEV + erlotinib (AUC 6 + 175 mg/m2 + 15 mg/kg + 150 mg). Since the evaluation of the efficacy indicated partial response, maintenance chemotherapy (BEV and erlotinib) was performed. Chemotherapy was continued for 9 months until the patient was in a progressive disease state with meningeal dissemination. He died 12 months after the initiation of chemotherapy, which is a longer period than the previously reported OS. Of note, according to our case, CBDCA + PTX + BEV + erlotinib and its maintenance chemotherapy are feasible and well tolerated for CUP.